Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. develops allosteric small molecule therapies for neurodegenerative and other difficult-to-treat diseases. The company’s lead candidate, GT-02287, is being developed for Parkinson’s disease with or without a GBA1 mutation and is designed as a brain-penetrant allosteric enzyme modulator of glucocerebrosidase, or GCase.
Recurring news for GANX includes financial results, corporate updates, clinical and biomarker data for GT-02287, FDA and IND-related communications, and scientific presentations at Parkinson’s and neurodegeneration conferences. Company updates also cover the Magellan™ drug discovery platform, preclinical GCase modulator programs such as GT-04686, and pipeline areas including lysosomal storage disorders, metabolic diseases and solid tumors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Gain Therapeutics, Inc. (Nasdaq: GANX) announced the appointment of C. Evan Ballantyne as Chief Financial Officer, effective immediately, succeeding Salvatore Calabrese. Ballantyne brings over 20 years of experience in healthcare finance, having previously served as CFO at OncXerna Therapeutics and Orchestra Biomed. He has a track record of raising significant capital, including $30 million at OncXerna and $57 million at Orchestra. Under his guidance, Gain Therapeutics aims to transition to a clinical-stage company with its lead program targeting GBA1 Parkinson's disease entering the clinic this year. The company has also granted Ballantyne equity awards as an inducement for joining. Gain Therapeutics focuses on allosteric small molecule therapies with a pipeline targeting neurodegenerative diseases and metabolic disorders.
Gain Therapeutics, Inc. (GANX) announced promising pre-clinical data supporting the potential therapeutic effects of its allosteric small molecule therapies for Alzheimer’s disease. Presented at the 2023 AD/PD Conference, the data shows that their compounds significantly improve neuronal survival and reduce toxicity from Amyloid Beta and Tau proteins in cell models. The STAR compounds exhibit disease-modifying properties, showcasing their potential to avert neurodegeneration associated with Alzheimer’s disease. Gain Therapeutics aims to advance research in allosteric regulators, with further updates expected throughout the year.
Gain Therapeutics (NASDAQ: GANX) reported significant progress in its pipeline and financial results for the year ending December 31, 2022. The company plans to submit a dossier for a Phase 1 clinical trial of GT-02287 for GBA1 Parkinson’s Disease by mid-2023. As of December 31, 2022, Gain had $22.1 million in cash and equivalents and received a €1.2 million non-dilutive grant for research in Alpha-1 Antitrypsin Deficiency. However, the net loss increased to $17.59 million compared to $13.89 million in 2021, primarily due to rising R&D and G&A expenses. The company expects existing funds to sustain operations into Q2 2024.